Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is a degenerative disease of the central nervous system characterized by an insidious onset and progressive worsening of cognitive function. The main pathological features of AD are β-amyloid (Aβ) plaques, neuroprogenitor fibril tangles (NFT) formed by hyperphosphorylated Tau proteins, and other pathological features. In addition, there is growing evidence that AD is strongly associated with microglia activation, due to the fact that most of the risk genes for AD are highly expressed by microglia in the brain. The category of microglia is mainly depending on the milieu in which they become activated and the factors they are stimulated. In the development of AD, microglia can be activated to the M1 type to exert neuroinflammatory effects by producing various pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 to induce neurotoxicity, and to the M2 type to exert anti-inflammation effects through enhancing the expression of neurotrophin, IL-4, and IL-6, and accelerate the clearance of Aβ plaques, which is believed to be promising molecules in AD therapy. This paper summarizes the mechanisms of microglia in AD and reviews the activation of microglia, the triggering receptor expressed on myeloid cells 2 (TREM2), disease-associated microglia (DAM), and gut microbiota to identify new therapeutic targets for AD, which currently lacks effective interventions.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: